Evoke Pharma Inc. (EVOK) Stock Price Up 12.1%
Evoke Pharma Inc. (NASDAQ:EVOK)’s share price rose 12.1% on Friday . The stock traded as high as $8.00 and last traded at $7.87, with a volume of 103,660 shares trading hands. The stock had previously closed at $7.02.
EVOK has been the topic of several research analyst reports. FBR & Co reissued a “buy” rating on shares of Evoke Pharma in a report on Saturday, May 14th. Ascendiant Capital Markets increased their price target on Evoke Pharma from $11.00 to $12.00 and gave the company a “buy” rating in a report on Monday, March 14th. Rodman & Renshaw reissued a “buy” rating and set a $27.00 price target on shares of Evoke Pharma in a report on Monday, March 14th. Brean Capital reissued a “buy” rating on shares of Evoke Pharma in a report on Thursday, May 12th. Finally, Northland Securities initiated coverage on Evoke Pharma in a report on Wednesday, March 16th. They set an “outperform” rating and a $16.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $17.47.
The company has a 50 day moving average of $6.04 and a 200-day moving average of $4.56. The company’s market capitalization is $60.67 million.
Evoke Pharma (NASDAQ:EVOK) last issued its quarterly earnings data on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities research analysts anticipate that Evoke Pharma Inc. will post ($1.37) earnings per share for the current fiscal year.
In related news, major shareholder Parters Vii L. P. Domain sold 41,478 shares of Evoke Pharma stock in a transaction that occurred on Wednesday, April 20th. The shares were sold at an average price of $5.35, for a total transaction of $221,907.30. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, major shareholder Parters Vii L. P. Domain sold 5,095 shares of Evoke Pharma stock in a transaction that occurred on Wednesday, April 27th. The shares were sold at an average price of $5.07, for a total transaction of $25,831.65. The disclosure for this sale can be found here.
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.